208 related articles for article (PubMed ID: 17332943)
1. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
Int J Oncol; 2007 Apr; 30(4):1019-28. PubMed ID: 17332943
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
4. Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.
Kanashiro CA; Schally AV; Varga JL; Hammann B; Halmos G; Zarandi M
Cancer Lett; 2005 Aug; 226(2):123-31. PubMed ID: 16039952
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
Kanashiro CA; Schally AV; Groot K; Armatis P; Bernardino AL; Varga JL
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15836-41. PubMed ID: 14660794
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K
Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
[TBL] [Abstract][Full Text] [Related]
9. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
[TBL] [Abstract][Full Text] [Related]
10. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
Kiaris H; Schally AV; Sun B; Armatis P; Groot K
Oncogene; 1999 Nov; 18(50):7168-73. PubMed ID: 10597318
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
13. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
Int J Cancer; 2004 Nov; 112(4):570-6. PubMed ID: 15382037
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
[TBL] [Abstract][Full Text] [Related]
15. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Cai RZ; Baker B; Hammann BD; Armatis P; Kanashiro CA
Eur J Cancer; 2005 Nov; 41(17):2735-44. PubMed ID: 16291086
[TBL] [Abstract][Full Text] [Related]
18. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival.
Decaussin M; Sartelet H; Robert C; Moro D; Claraz C; Brambilla C; Brambilla E
J Pathol; 1999 Aug; 188(4):369-77. PubMed ID: 10440746
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
